Last reviewed · How we verify
Basal insulin
Basal insulin, marketed by Mayo Clinic, is a long-acting insulin analog used in the management of diabetes, currently holding a position in a highly competitive market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports revenue generation. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and financial performance.
At a glance
| Generic name | Basal insulin |
|---|---|
| Also known as | (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk), LY2963016, insulin glargine, insulin degludec, insulin detemir |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Surgical or Medical Treatment (PHASE4)
- INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (PHASE2)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (PHASE1)
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
- Optimization of Basal Insulin During Ramadan Fasting in Type 2 Diabetic Patients: Comparison Between DAR Recommendations and the Carbohydrate Fasting Test & Metabolic and Inflammatory Consequences (EARLY_PHASE1)
- The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants. (NA)
- A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basal insulin CI brief — competitive landscape report
- Basal insulin updates RSS · CI watch RSS
- Mayo Clinic portfolio CI